A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Gupta, Charu
- Induction Therapy in Pediatric Renal Transplantation: Current Perspective
Authors
1 1.5-100, West Wing Department of Nephrology Children’s National Medical Center 111, Michigan Avenue, NW Washington, DC, 20010, US
2 Department of Nephrology, Children’s National Medical Center, Washington, DC, US
Source
Journal of Clinical Pediatric Nephrology, Vol 2, No 2 (2013), Pagination: 1-10Abstract
Induction therapy is used to manipulate transplant recipients’ immune system to prevent acute rejection (AR) and immune mediated graft loss in the first few months. Historically, potent induction targeted at T-cells was used until maintenance immunosuppression could take effect. With modern maintenance immunosuppression, improved human leukocyte antigen (HLA) typing, cross-match and precise identification of anti-HLA antibodies, AR incidence has fallen significantly except in high-risk patients. Therefore, an increased need for devising targeted induction based on risk stratification for AR including targeting B-cells and complement has been recognized. Specific induction protocols are needed in children with end-stage renal disease (ESRD) due to focal segmental glomerulosclerosis (FSGS) and atypical hemolytic uremic syndrome (aHUS) to prevent disease recurrence. Induction is modified to avoid long-term steroids and to minimize nephrotoxic calcineurin inhibitor (CNI) exposure. Current data suggests that anti-interleukin-2 receptor and lymphocyte depleting antibodies may improve short-term graft survival in standard-risk and high-risk patients respectively; though effect on long-term graft survival has not been shown. In highly sensitized and those with a positive cross-match or ABO incompatible transplants, treatment with intravenous immunoglobulin, plasmapheresis and rituximab may be indicated. In children with ESRD due to FSGS and aHUS, pre-transplant plasmapheresis is useful. Eculizumab has replaced plasmapheresis in children with aHUS. Extended anti-IL-2R therapy or Thymoglobulin have been useful for steroid avoidance and Alemtuzumab for immunosuppression minimization. Belatacept induction and maintenance to avoid CNI use is under investigation. Tolerance protocols including recipient T-cell depletion and donor bone marrow or stem cell infusions are under way.Keywords
Thymoglobulin, Basiliximab, Intravenous Immunoglobulin, RituximabReferences
- Moudgil A, Puliyanda D. Induction therapy in pediatric renal transplant recipients: An overview. Paediatric drugs. 2007;9(5):323-41. Epub 2007/10/12.
- Hardinger KL, Brennan DC, Klein CL. Selection of induction therapy in kidney transplantation. Transplant international: Official journal of the European Society for Organ Transplantation, 2012. Epub 2013/01/03.
- Levin B, Hoppe RT, Collins G, Miller E, Waer M, Bieber C, et al. Treatment of cadaveric renal transplant recipients with total lymphoid irradiation, antithymocyte globulin and low-dose prednisone. Lancet 1985;2(8468):1321-5. Epub 1985/12/14.
- Najarian JS, Ferguson RM, Sutherland DE, Slavin S, Kim T, Kersey J, et al. Fractionated total lymphoid irradiation as preparative immunosuppression in high risk renal transplantation: Clinical and immunological studies. Annals of surgery 1982;196(4):442- 52. Epub 1982/10/01.
- Slavin S, Strober S, Fuks Z, Kaplan HS. Immuno-suppression and organ transplantation tolerance using total lymphoid irradiation. Diabetes 1980;29 Suppl 1:121-3. Epub 1980/01/01.
- Myburgh JA, Smit JA, Stark JH, Browde S. Total lymphoid irradiation in kidney and liver transplantation in the baboon: Prolonged graft survival and alterations in T cell subsets with low cumulative dose regimens. J Immunol 1984;132(2):1019- 25. Epub 1984/02/01.
- Almond PS, Matas AJ, Gillingham K, Moss A, Mauer M, Chavers B, et al. Pediatric renal transplants—Results with sequential immunosuppression. Transplantation 1992;53(1):46-51. Epub 1992/01/01.
- Norman DJ, Kahana L, Stuart FP, Jr., Thistlethwaite JR, Jr., Shield CF, 3rd, Monaco A, et al. A randomized clinical trial of induction therapy with OKT3 in kidney transplantation. Transplantation 1993;55(1):44-50. Epub 1993/01/01.
- Caillard S, Dharnidharka V, Agodoa L, Bohen E, Abbott K. Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation 2005;80(9):1233-43.
- Opelz G, Mickey MR, Terasaki PI. Blood transfusions and unresponsiveness to HL-A. Transplantation 1973; 16(6): 649- 54. Epub 1973/12/01.
- Baron PW, Ojogho ON, Yorgin P, Sahney S, Cutler D, Ben-Youssef R, et al. Comparison of outcomes with low-dose anti-thymocyte globulin, basiliximab or no induction therapy in pediatric kidney transplant recipients: A retrospective study. Pediatric transplantation 2008;12(1):32-9. Epub 2008/01/12.
- Zamora I, Berbel O, Simon J, Sanahuja MJ. [Anti-CD25 monoclonal antibody against polyclonal antibodies in pediatric renal transplantation]. Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 2002;22(1):66-70. Epub 2002/ 05/04. Anticuerpo monoclonal anti-CD25 frente a anticuerpos policlonales en el trasplante renal pediatrico.
- Sampaio MS, Poommipanit N, Kuo HT, Reddy PN, Cho YW, Shah T, et al. Induction therapy in pediatric kidney transplant recipients discharged with a triple drug immunosuppressive regimen. Pediatric transplantation 2010;14(6):770-8. Epub 2010/05/19.
- Bourdage JS, Hamlin DM. Comparative polyclonal antithymocyte globulin and antilymphocyte/antilymphoblast globulin anti-CD antigen analysis by flow cytometry. Transplantation 1995;59(8):1194-200. Epub 1995/04/27.
- Woodside KJ, Hu M, Gugliuzza KK, Hunter GC, Daller JA. Tlymphocyte apoptosis is increased by non-interleukin-2- dependent induction in human mixed lymphocyte cultures. Transplantation proceedings 2005;37(4):1949-52. Epub 2005/ 05/28.
- Brennan DC, Flavin K, Lowell JA, Howard TK, Shenoy S, Burgess S, et al. A randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation 1999;67(7):1011-8. Epub 1999/04/30.
- Hardinger KL, Schnitzler MA, Miller B, Lowell JA, Shenoy S, Koch MJ, et al. Five-year follow up of thymoglobulin versus ATGAM induction in adult renal transplantation. Transplantation 2004;78(1):136-41. Epub 2004/07/17.
- Ault BH, Honaker MR, Osama Gaber A, Jones DP, Duhart Jr BT, Powell SL, et al. Short-term outcomes of Thymoglobulin induction in pediatric renal transplant recipients. Pediatr Nephrol 2002;17(10):815-8. Epub 2002/10/12.
- Khositseth S, Matas A, Cook ME, Gillingham KJ, Chavers BM. Thymoglobulin versus ATGAM induction therapy in pediatric kidney transplant recipients: A single-center report. Transplantation 2005;79(8):958-63. Epub 2005/04/26.
- Brophy PD, Thomas SE, McBryde KD, Bunchman TE. Comparison of polyclonal induction agents in pediatric renal transplantation. Pediatric transplantation 2001; 5(3):174-8. Epub 2001/06/26.
- Calne R, Moffatt SD, Friend PJ, Jamieson NV, Bradley JA, Hale G, et al. Campath IH allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients. Transplantation 1999;68(10):1613-6. Epub 1999/12/10.
- Knechtle SJ, Pirsch JD, H. Fechner J J, Becker BN, Friedl A, Colvin RB, et al. Campath-1H induction plus rapamycin monotherapy for renal transplantation: Results of a pilot study. American journal of transplantation : Official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2003;3(6):722-30. Epub 2003/06/05.
- Ciancio G, Burke GW, Gaynor JJ, Mattiazzi A, Roohipour R, Carreno MR, et al. The use of Campath-1H as induction therapy in renal transplantation: Preliminary results. Transplantation 2004;78(3):426-33. Epub 2004/08/19.
- Watson CJ, Bradley JA, Friend PJ, Firth J, Taylor CJ, Bradley JR, et al. Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation—Efficacy and safety at five years. American journal of transplantation : Official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2005;5(6):1347-53. Epub 2005/ 05/13.
- Knechtle SJ, Fernandez LA, Pirsch JD, Becker BN, Chin LT, Becker YT, et al. Campath-1H in renal transplantation: The University of Wisconsin experience. Surgery 2004;136(4):754- 60. Epub 2004/10/07.
- Kaufman DB, Leventhal JR, Axelrod D, Gallon LG, Parker MA, Stuart FP. Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: Comparison with basiliximab induction—Long-term results. American journal of transplantation : Official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2005;5(10):2539-48. Epub 2005/09/16.
- Tan HP, Donaldson J, Ellis D, Moritz ML, Basu A, Morgan C, et al. Pediatric living donor kidney transplantation under alemtuzumab pretreatment and tacrolimus monotherapy: 4-year experience. Transplantation. 2008;86(12):1725-31. Epub 2008/12/24.
- Velez C, Zuluaga G, Ocampo C, Aristizabal A, Serna LM, Serrano Gayubo AK, et al. Clinical description and evolution of renal transplant pediatric patients treated with alemtuzumab. Transplantation proceedings 2011; 43(9):3350-4. Epub 2011/ 11/22.
- Bartosh SM, Knechtle SJ, Sollinger HW. Campath-1H use in pediatric renal transplantation. American journal of transplantation: Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2005;5(6):1569-73. Epub 2005/05/13.
- De Serres SA, Mfarrej BG, Magee CN, Benitez F, Ashoor I, Sayegh MH, et al. Immune profile of pediatric renal transplant recipients following alemtuzumab induction. Journal of the American Society of Nephrology:JASN 2012;23(1):174-82. Epub 2011/11/05.
- Vo AA, Wechsler EA, Wang J, Peng A, Toyoda M, Lukovsky M, et al. Analysis of subcutaneous (SQ) alemtuzumab induction therapy in highly sensitized patients desensitized with IVIG and rituximab. American journal of transplantation: Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2008;8(1):144-9. Epub 2007/ 11/02.
- Jordan SC, Vo AA, Peng A, Toyoda M, Tyan D. Intravenous gammaglobulin (IVIG): A novel approach to improve transplant rates and outcomes in highly HLA-sensitized patients. American journal of transplantation: Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2006; 6(3):459-66. Epub 2006/02/14.
- Jordan SC, Tyan D, Czer L, Toyoda M. Immunomodulatory actions of intravenous immunoglobulin (IVIG): Potential applications in solid organ transplant recipients. Pediatric transplantation 1998;2(2):92-105. Epub 1999/03/19.
- O’Dwyer ME, Launder T, Rabkin JM, Nichols CR. Successful treatment of aggressive post transplant lymphoproliferative disorder using rituximab. Leukemia and lymphoma 2000;39(3- 4):411-9. Epub 2001/05/09.
- Tyden G, Kumlien G, Genberg H, Sandberg J, Lundgren T, Fehrman I. ABO incompatible kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab. American journal of transplantation: Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2005;5(1):145-8. Epub 2005/ 01/08.
- Donauer J, Wilpert J, Geyer M, Schwertfeger E, Kirste G, Drognitz O, et al. ABO-incompatible kidney transplantation using antigenspecific immunoadsorption and rituximab: A single center experience. Xenotransplantation 2006;13(2):108-10. Epub 2006/ 04/21.
- Sawada T, Fuchinoue S, Teraoka S. Successful A1-to-O ABOincompatible kidney transplantation after a preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy, and double-filtration plasmapheresis. Transplantation 2002; 74(9):1207-10. Epub 2002/11/27.
- Sawada T, Fuchinoue S, Kawase T, Kubota K, Teraoka S. Preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy and DFPP-enabled nonresponders to undergo ABO-incompatible kidney transplantation. Clinical transplantation 2004; 18(3):254-60. Epub 2004/05/15.
- Woodle ES, Walsh RC, Alloway RR, Girnita A, Brailey P. Proteasome inhibitor therapy for antibody-mediated rejection. Pediatric transplantation 2011;15(6):548-56. Epub 2011/09/03.
- Asgari E, Zhou W, Sacks S. Complement in organ transplantation. Current opinion in organ transplantation 2010;15(4):486-91. Epub 2010/07/16.
- Barnett AN, Asgari E, Chowdhury P, Sacks SH, Dorling A, Mamode N. The use of eculizumab in renal transplantation. Clinical transplantation 2013. Epub 2013/03/23.
- Matas AJ, Smith JM, Skeans MA, Lamb KE, Gustafson SK, Samana CJ, et al. OPTN/SRTR 2011 Annual Data Report: Kidney. American journal of transplantation: Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2013;13 Suppl 1:11-46. Epub 2013/01/ 31.
- Stegall MD, Diwan T, Raghavaiah S, Cornell LD, Burns J, Dean PG, et al. Terminal complement inhibition decreases antibodymediated rejection in sensitized renal transplant recipients. American journal of transplantation: Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2011;11(11):2405-13. Epub 2011/09/ 29.
- Wood KJ, Goto R. Mechanisms of rejection: Current perspectives. Transplantation 2012;93(1):1-10. Epub 2011/12/ 06.
- Hanaway MJ, Woodle ES, Mulgaonkar S, Peddi VR, Kaufman DB, First MR, et al. Alemtuzumab induction in renal transplantation. The New England Journal of Medicine 2011;364(20):1909-19. Epub 2011/05/20.
- Chikamoto H, Hattori M, Kuroda N, Kajiho Y, Matsumura H, Fujii H, et al. Pretransplantation combined therapy with plasmapheresis and rituximab in a second living-related kidney transplant pediatric recipient with a very high risk for focal segmental glomerulosclerosis recurrence. Pediatric transplantation 2012;16(7):E286-90. Epub 2011/12/02.
- Zuber J, Le Quintrec M, Krid S, Bertoye C, Gueutin V, Lahoche A, et al. Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. American journal of transplantation: Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2012;12(12):3337-54. Epub 2012/09/11.
- Dharnidharka VR, Stevens G. Risk for post-transplant lymphoproliferative disorder after polyclonal antibody induction in kidney transplantation. Pediatric transplantation 2005;9(5):622-6. Epub 2005/09/24.
- Pestana JO, Grinyo JM, Vanrenterghem Y, Becker T, Campistol JM, Florman S, et al. Three-year outcomes from BENEFIT-EXT: A phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys. American journal of transplantation: Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2012;12(3):630-9. Epub 2012/02/04.
- Luo G, Falta EM, Elster EA. Steroid-free immuno-suppression in organ transplantation. Current diabetes reports 2005;5(4):305- 10. Epub 2005/07/22.
- Birkeland SA. Steroid-free immunosuppression in renal transplantation. Lancet 1996;348(9034):1105-6. Epub 1996/10/ 19.
- Birkeland SA. Steroid-free immunosuppression after kidney transplantation with anti-thymocyte globulin induction and cyclosporine and mycophenolate mofetil maintenance therapy. Transplantation 1998;66(9):1207-10. Epub 1998/11/24.
- Sarwal MM, Ettenger RB, Dharnidharka V, Benfield M, Mathias R, Portale A, et al. Complete steroid avoidance is effective and safe in children with renal transplants: A multicenter randomized trial with three-year follow-up. American journal of transplantation: Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2012; 12(10): 2719-29. Epub 2012/06/15.
- Scandling JD, Busque S, Shizuru JA, Engleman EG, Strober S. Induced immune tolerance for kidney transplantation. The New England Journal of Medicine 2011;365(14):1359-60. Epub 2011/ 10/14.
- Leventhal J, Abecassis M, Miller J, Gallon L, Tollerud D, Elliott MJ, et al. Tolerance induction in HLA disparate living donor kidney transplantation by donor stem cell infusion: Durable chimerism predicts outcome. Transplantation 2013;95(1):169-76. Epub 2012/12/12.
- Wojciechowski D, Vincenti F. Belatacept in kidney transplantation. Current opinion in organ transplantation 2012;17(6):640-7. Epub 2012/10/10.
- http://www.clinicaltrials.gov/
- Vincenti F, Tedesco Silva H, Busque S, O’Connell P, Friedewald J, Cibrik D, et al. Randomized phase 2b trial of tofacitinib (CP- 690,550) in de novo kidney transplant patients: Efficacy, renal function and safety at 1 year. American journal of transplantation 2012;12(9):2446-56. Epub 2012/06/12.
- Vincenti F. Are calcineurin inhibitors-free regimens ready for prime time? Kidney International 2012;82(10):1054-60. Epub 2012/05/25.
- Effect of Acu-TENS on Pulmonary Functions in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Authors
1 Dashmesh College of Physiotherapy, SGT Group of Institutions, Budhera Gurgaon, IN
2 Faridabad Institute of Technology, Faridabad, IN
Source
Indian Journal of Physiotherapy & Occupational Therapy-An International Journal, Vol 6, No 4 (2012), Pagination: 115-119Abstract
Background: Acu-TENS has been used to relieve dyspnea and to improve pulmonary function in a variety of respiratory disease patients. There is limited evidence for the use of Acu-TENS in patients with acute exacerbation of chronic obstructive disease.
Purpose: The purpose of the present study was to find out the effect of Acu-TENS on pulmonary function in patients with acute exacerbation of COPD.
Design: Randomized pretest-posttest experimental design.
Methods: Total thirty COPD patients with acute exacerbation, were randomly assigned to receive either Acu-TENS or Placebo Acu-TENS for 5 days. Dyspnea score, FEV1 and FVC were measured on 1st, 3rd and 5th day.
Results: Data analysis was performed by SPSS 16. It was found that a statistically significant improvement occurred in dyspnea score, FEV1 and FVC in both the groups. This improvement was significantly higher in patients in Group A as compared to that in Group B.
Limitations: The results of the spirometery were subjected to patient's effort and motivational factor; and effect of TENS or placebo TENS over acupuncture points was compared rather than TENS applied over non acupuncture points.
Conclusion: Results of the study offer an exciting new opportunity to provide a non-pharmacological and non-airflow dependent treatment modality to emergency department practice for acute exacerbation of COPD.
Keywords
Acute exacerbation, COPD, Dyspnea, FEV1, FVC, Acu-TENSReferences
- F. Klaus, H. Suzanne et al. Global strategy for the diagnosis, management and prevention of chronic pulmonary disease. Am J Respir Crit Care Med 2007; 176: 532-555.
- Lau KSL, Jones AYM. A single session of Acu-TENS increases FEV1 and reduces dyspnea in patients with COPD: a randomized, placebocontrolled trial. Australian Journal of Physiotherapy 2008; 54: 179-184.
- Seemungal TA, Donaldson GC et al. Effect of exacerbation on quality of life in patients with COPD. Am J Respir Crit Care Med 1998; 157:1418–1422.
- National Heart, Lung and Blood Institute (NHLBI). Global strategy for the diagnosis, management, and prevention of COPD. NHLBI/WHO workshop report. Updated 2005.
- Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest 2000; 117(5 Suppl 2):398S-401S.
- Polkey M I. Muscle metabolism and exercise tolerance in COPD. Chest 121; 131S-135S.
- Stevenson NJ, Walker PP et al. Lung mechanics and dyspnea during exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;172(12):1510-1516.
- Cyanthia X. Pan MD et al. Complementary and Alternative medicine in the management of Pain, Dyspnea, and Nausea and Vomiting near the End of Life: A Systematic Review. J Pain Symptom Manag 2000; 20: 374-387
- Cho ZH, Hwang SC et al. Neural substrates, experimental evidences and functional hypothesis of acupuncture mechanisms. Acta Neurologica Scandinavica 2006; 113: 370-377.
- Peuker E, Gronemer D. Rare nut serious complications of acupuncture: traumatic lesions. Acupuncture in Medicine 2001; 19: 103-108.
- Wouters EF. Management of severe COPD. Lancet 2004; 364: 883-895.
- Rochester DF, Braun NM. Determinants of maximal inspiratory pressure in chronic obstructive pulmonary disease. Am Rev Respir Dis 1985; 132:42-47
- M Suzuki, K Nimura et al. The effect of acupuncture in the treatment of COPD. Journal of Alternative and Complementary Medicine 2008; 14(9): 1097-1105
- Sepulveda P, Bohilla G, Hoffmann T. Treatment of asthmatic bronchoconstriction by percutaneous low voltage nerve stimulation: Case report. Internet J Asthma, Allergy and Immunology 2009; 7(2)
- Cardiopulmonary Physiolo Chi- East meets West via Acu TENS.
- Shirly PC Negi, Alice YM Jones et al. Effect of Acu-TENS on post exercise expiratory lung volume in subjects with asthma-A randomized controlled trial. Respiratory Physiology & Neurology 2009; 167(3): 348-353.
- Jobst K, Chen JH et al. Controlled trial of acupuncture for disabling breathlessness. Lancet 1986; 20: 1416-1419.
- Bellofiore S, DiMaria GU, Priviteria S et al. Endogenous opoids modulate the increase in ventilator output and dyspnea during severe acute bronchoconstriction. American Review of Respiratory Disease 1990; 142: 812-816.